FrancophonIA/ELRC3.0 huggingface dataset:
English: All patients should be monitored for a period of 6 hours for signs and symptoms of bradycardia with hourly heart rate and blood pressure measurement.
Slovenian: Vsem bolnikom je treba pred prejemom prvega odmerka zdravila Gilenya in 6 ur po njem posneti EKG in izmeriti krvni tlak .Vse bolnike je treba v obdobju teh 6 ur spremljati glede znakov in simptomov bradikardije in jim vsako uro izmeriti krvni tlak in srčno frekvenco.
English: One capsule contains 0.5 mg fingolimod (as hydrochloride).
Slovenian: Ena kapsula vsebuje 0,5 mg fingolimoda (v obliki klorida).
English: Infections and infestations Very common:
Slovenian: Bolezni prebavil zelo pogosti:
English: Gilenya 0.5 mg hard capsules
Slovenian: Gilenya 0,5 mg trde kapsule
English: Rare cases of unusually large brain lesions associated with MS relapse have been reported in patients treated with Gilenya.
Slovenian: Neobičajne spremembe na možganih v povezavi z zagonom multiple skleroze Pri bolnikih, ki so prejemali zdravilo Gilenya, so poročali o redkih primerih pojavljanja neobičajno velikih lezij v možganih v povezavi z zagoni multiple skleroze.
English: • Other medicines: o protease inhibitors, anti-infectives such as ketoconazole, azole antifungals, clarithromycin or telithromycin.
Slovenian: • druga zdravila: o zaviralce proteaz, zdravila za zdravljenje okužb, kot so ketokonazol, azolna protiglivična zdravila, klaritromicin ali telitromicin, o karbamazepin, rifampicin, fenobarbital, fenitoin, efavirenz ali šentjanževko (obstaja tveganje za zmanjšano učinkovitost zdravila Gilenya).
English: The patient should be referred to a dermatologist in case suspicious lesions are detected.
Slovenian: V primeru suspektne kožne spremembe je treba bolnika napotiti k dermatologu.
English: A type of cancer of the lymphatic system (lymphoma) has been reported in MS patients treated with Gilenya.
Slovenian: Pri bolnikih z multiplo sklerozo, ki so prejemali zdravilo Gilenya, so poročali o vrsti raka, ki se razvije v limfatičnem sistemu (o limfomu).
English: Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported in patients treated with Gilenya.
Slovenian: Pri bolnikih, ki so prejemali zdravilo Gilenya, so poročali o okužbah s humanim papiloma virusom (HPV), kar vključuje papilome, displazijo, bradavice in raka, ki ga povzroča HPV.
English: GILENYA 0.25 mg hard capsules fingolimod
Slovenian: GILENYA 0.25 mg trde kapsule fingolimod
English: Gilenya 0.25 mg hard capsules
Slovenian: Gilenya 0,25 mg trde kapsule
English: Patients should be referred to a dermatologist if suspicious lesions are detected.
Slovenian: V primeru odkritja sumljive kožne spremembe je treba bolnika napotiti k dermatologu.
English: If GILENYA treatment is considered in these patients anticipated benefits must outweigh potential risks and a cardiologist must be consulted to switch to non heart-ratelowering therapy or, if not possible, to determine appropriate monitoring.
Slovenian: Če je pri teh bolnikih predvideno zdravljenje z zdravilom GILENYA, morajo pričakovane koristi presegati možna tveganja, s kardiologom pa se je treba posvetovati glede zamenjave navedenih zdravil za druga zdravila, ki ne znižujejo srčne frekvence.
English: GILENYA 0.5 mg hard capsules fingolimod
Slovenian: GILENYA 0,5 mg trde kapsule fingolimod
English: • Seizure monitoring guidance.
Slovenian: • navodila za spremljanje pojavljanja epileptičnih napadov.
English: Mild isolated bilirubin increases have been noted in paediatric patients on fingolimod.
Slovenian: Pri pediatričnih bolnikih, ki so prejemali fingolimod, so opažali izolirano blago zvišanje vrednosti bilirubina.
English: One capsule contains 0.25 mg fingolimod (as hydrochloride).
Slovenian: Ena kapsula vsebuje 0,25 mg fingolimoda (v obliki klorida).
English: Bradycardia-inducing substances
Slovenian: Učinkovine, ki povzročajo bradikardijo
English: Cases of seizures, including status epilepticus, have been reported with the use of Gilenya in clinical studies and in the post-marketing setting.
Slovenian: Pri uporabi zdravila Gilenya v kliničnih študijah in po prihodu zdravila na trg so poročali o primerih epileptičnih napadov, kar vključuje epileptični status.
English: The desired effect of Gilenya treatment is to reduce the amount of white blood cells in your blood.
Slovenian: Zmanjšanje števila belih krvnih celic v krvi je zaželen učinek zdravila Gilenya.
English: Skin cancers have been reported in MS patients treated with Gilenya.
Slovenian: Pri bolnikih z multiplo sklerozo, ki so prejemali zdravilo Gilenya, so poročali o kožnih rakih.
English: Fingolimod had no effect on sperm count/motility or on fertility in male and female rats up to the highest dose tested (10 mg/kg), representing an approximate 150-fold margin based on human systemic exposure (AUC) at a daily dose of 0.5 mg.
Slovenian: Fingolimod do najvišjega testiranega odmerka (10 mg/kg), kar predstavlja približno 150-kratnik mejne vrednosti glede na sistemsko izpostavljenost (AUC) pri ljudeh pri odmerku 0,5 mg, ni vplival niti na število ali mobilnost semenčic niti na plodnost pri samcih in samicah podgan.
English: Symptoms may include sudden onset of severe headache, confusion, seizures and/or vision disturbances - Lymphoma (a type of cancer that affects the lymph system) - Squamous cell carcinoma: a type of skin cancer which may present as a firm red nodule, a sore with crust, or a new sore on an existing scar
Slovenian: Redki (lahko se pojavijo pri največ 1 od 1.000 ljudi): - bolezen, ki se imenuje sindrom posteriorne reverzibilne enecefalopatije (angl. posterior reversible encephalopathy syndrome, s kratico PRES): simptomi lahko vključujejo hud glavobol z nenadnim začetkom, zmedenost, epileptične napade in/ali motnje vida, - limfom (vrsta raka, ki prizadene limfni sistem), - ploščatocelični karcinom: vrsta kožnega raka, ki je lahko videti kot čvrst rdeč vozliček, rana s krasto ali nastanek nove rane na že prej prisotni brazgotini.
English: In case of T-wave inversion, the prescriber should ensure that there are no associated myocardial ischaemia signs or symptoms.
Slovenian: Pri odraslih bolnikih, ki so prejemali fingolimod, so poročali o zelo redkih primerih inverzije vala T. Če pride do inverzije vala T, mora zdravnik, ki predpisuje zdravilo, preveriti, da bolnik nima hkrati tudi znakov ali simptomov ishemije miokarda.
English: - Mild isolated bilirubin increases have been noted in paediatric patients on Gilenya.
Slovenian: - Pri pediatričnih bolnikih, ki so prejemali zdravilo Gilenya, so opažali izolirano blago zvišanje vrednosti bilirubina.
English: Check varicella zoster virus (VZV) antibody status in patients without a healthcare professional confirmed history of chickenpox or documentation of a full course of varicella vaccination.
Slovenian: Bolniki, pri katerih anamneze noric ni potrdil zdravstveni delavec oziroma nimajo dokumentacije o opravljenem celotnem cepljenju proti virusu noric, naj opravijo testiranje na prisotnost protiteles proti virusu varicella-zoster.
English: Some side effects could be or could become serious Common (may affect up to 1 in 10 people): - Coughing with phlegm, chest discomfort, fever (signs of lung disorders) - Herpes virus infection (shingles or herpes zoster) with symptoms such as blisters, burning,
Slovenian: Zelo pogosti (lahko se pojavijo pri več kot 1 od 10 ljudi): - okužba z virusom gripe s simptomi, kot so utrujenost, mrazenje, boleče grlo oziroma žrelo,
English: Each 0.5 mg capsule contains 0.5 mg fingolimod (as hydrochloride).
Slovenian: Ena 0,5-miligramska kapsula vsebuje 0,5 mg fingolimoda (v obliki klorida).
English: Median (mean) % change in brain volume over 12 months † Disability progression defined as 1-point increase in EDSS confirmed 3 months later.
Slovenian: Cilji opazovanja pri slikanju z MR mediana števila novih ali povečanih lezij T2 v 12 mesecih mediana števila lezij po okrepitvi z gadolinijem (Gd) po 12 mesecih mediana odstotne spremembe prostornine možganov v 12 mesecih † napredovanje invalidnosti, opredeljeno s poslabšanjem na lestvici EDSS za 1 točko,
English: Median (mean) % change in brain volume over 24 months † Disability progression defined as 1-point increase in EDSS confirmed 3 months later ** p<0.001 compared to placebo
Slovenian: Cilji opazovanja pri slikanju z MR mediana (povprečje) števila novih ali povečanih lezij T2 v 24 mesecih mediana (povprečje) števila lezij po okrepitvi z gadolinijem (Gd) po 24 mesecih mediana (povprečje) odstotne spremembe prostornine možganov v 24 mesecih † napredovanje invalidnosti, opredeljeno s poslabšanjem na lestvici EDSS za 1 točko,
English: Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPV-related cancer, has been reported under treatment with fingolimod in the post-marketing setting.
Slovenian: V okviru zdravljenja s fingolimodom po prihodu zdravila na trg so poročali o okužbah s humanim papiloma virusom (HPV), kar vključuje papilome, displazijo, bradavice in raka, ki ga povzroča HPV.
English: Each 0.25 mg capsule contains 0.25 mg fingolimod (as hydrochloride).
Slovenian: Ena 0,25-miligramska kapsula vsebuje 0,25 mg fingolimoda (v obliki klorida).
English: Very common (may affect more than 1 in 10 people): - Infection from flu virus with symptoms such as tiredness, chills, sore throat, aching in the joints or muscles, fever - Feeling of pressure or pain in the cheeks and forehead (sinusitis) - Headache - Diarrhoea - Back pain - Blood testing showing higher levels of liver enzymes - Cough
Slovenian: bolečine v sklepih ali mišicah, zvišana telesna temperatura, - občutek pritiska ali bolečina v predelu lic ali čela (vnetje sinusov), - glavobol, - diareja, - bolečine v hrbtu, - zvišane vrednosti jetrnih encimov pri krvnih preiskavah, - kašelj.
English: o Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts and HPVrelated cancer, has been reported in the post-marketing setting.
Slovenian: o V okviru izkušenj v obdobju trženja so poročali o okužbah s humanim papiloma virusom (HPV), kar vključuje papilome, displazijo, bradavice in raka, ki ga povzroča HPV.
English: Recent (i.e. within last 6 months) transaminase and bilirubin levels should be available before initiation of treatment with Gilenya.
Slovenian: Pred začetkom zdravljenja z zdravilom Gilenya je treba pridobiti nedavne podatke o vrednostih aminotransferaz in bilirubina (v času zadnjih 6 mesecev).
English: As this could potentially impair the efficacy, their co-administration should be used with caution.
Slovenian: Ker bi to lahko zmanjšalo učinkovitost, je pri sočasni uporabi navedenih učinkovin potrebna previdnost, sočasna uporaba šentjanževke pa ni priporočena (glejte poglavje 4.4).
English: This increase persisted with continued treatment.
Slovenian: Ob nadaljevanju zdravljenja je tudi krvni tlak ostal zvišan.
English: Gilenya 0.5 mg hard capsules have a white opaque body and bright yellow opaque cap. “FTY0.5mg” is imprinted on the cap with black ink and two bands are imprinted on the body with yellow ink.
Slovenian: Trde kapsule Gilenya 0,5 mg imajo belo neprozorno telo in svetlo rumen neprozoren pokrovček.
English: Caution regarding potential concomitant immune effects is required when switching patients from natalizumab or teriflunomide to Gilenya.
Slovenian: Pri prehodu bolnikov z zdravljenja z natalizumabom ali teriflunomidom na jemanje zdravila Gilenya je potrebna previdnost zaradi možnosti sočasnega delovanja na imunski sistem.
English: • Liver function should be monitored at months 1, 3, 6, 9 and 12 during GILENYA therapy and periodically thereafter; the approved dosing of 0.5 mg daily (or 0.25 mg once daily in pediatric patients 10 years of age and above with a body weight of ≤40 kg) should be administered.
Slovenian: Pri ponovni uvedbi zdravila GILENYA je treba zdravilo jemati v skladu z odobrenim odmerjanjem 0,5 mg enkrat na dan (oziroma z odmerjanjem 0,25 mg enkrat na dan pri pediatričnih bolnikih, ki so stari 10 let ali več in imajo telesno maso ≤40 kg).
English: Repeat the first dose monitoring after the second dose of GILENYA; o Extend heart rate monitoring for at least overnight in a medical facility and until resolution of findings in patients:
Slovenian: o Spremljanje srčne frekvence v zdravstveni ustanovi je treba pri bolniku podaljšati najmanj preko noči in dokler ugotovljene motnje ne izzvenijo:
English: Eye disorders Common:
Slovenian: zamegljen vid občasni:
English: Median (mean) number of new or enlarging T2 lesions over 12 months
Slovenian: Cilji opazovanja pri slikanju z MR na eno leto preračunana stopnja števila novih ali povečanih lezij T2
English: • Any symptoms of visual impairment should be reported immediately to the prescriber during and for up to two months after the end of treatment with GILENYA;
Slovenian: • Bolniki morajo v primeru simptomov okvare vida v času zdravljenja in do dva meseca po prekinitvi zdravljenja z zdravilom GILENYA takoj obvestiti zdravnika, ki je predpisal zdravilo.
English: Mannitol
Slovenian: astenija
English: o A negative pregnancy test result must be confirmed prior to starting treatment.
Slovenian: o Pred začetkom zdravljenja morajo bolnice opraviti test nosečnosti, ki mora biti negativen.
English: • A pregnancy test must be carried out and negative results verified by the doctor before starting treatment.
Slovenian: • Pred začetkom zdravljenja mora bolnica opraviti test nosečnosti.
English: Other symptoms may be fever and weakness in the early stages of infection, followed by numbness, itching or red patches with severe pain - Slow heartbeat (bradycardia), irregular heart rhythm - A type of skin cancer called basal cell carcinoma (BCC) which often appears as a pearly nodule,
Slovenian: Nekateri neželeni učinki so lahko resni oziroma lahko postanejo resni Pogosti (lahko se pojavijo pri največ 1 od 10 ljudi): - kašljanje z izkašljevanjem sluzi, občutek nelagodja v prsnem košu in zvišana telesna temperatura (znaki pljučnih bolezni), - okužba s herpes virusom (norice (vodene koze) ali herpes zoster (pasovec)) s simptomi, kot so mehurčki, pekoč občutek, srbenje ali bolečine na koži, praviloma na zgornjem delu telesa oziroma na obrazu, drugi simptomi so lahko zvišana telesna temperatura in šibkost v zgodnji fazi okužbe, nato pa odrevenelost, srbenje ali zelo boleče rdeče lise, - počasno bitje srca (bradikardija), nepravilen srčni ritem, - vrsta kožnega raka, ki ga imenujemo bazalnocelični karcinom, ki je pogosto videti kot vozliček s svetlečo biserno površino, lahko pa je tudi drugačne oblike, - znano je, da se depresija in tesnoba pogosteje pojavljata v populaciji bolnikov z multiplo sklerozo in o njiju so poročali tudi pri pediatričnih bolnikih, ki so prejemali zdravilo Gilenya, - hujšanje.
English: If lymphoma is suspected, Gilenya should be discontinued.
Slovenian: V primeru suma na limfom je treba uporabo zdravila Gilenya pre kiniti.
English: Initiation of treatment with Gilenya should be delayed in patients with severe active infection until resolution.
Slovenian: Pri bolnikih s hudo okužbo je treba zdravljenje z zdravilom Gilenya odložiti do ozdravitve.
English: What Gilenya looks like and contents of the pack Gilenya 0.25 mg hard capsules have an ivory opaque body and cap. “FTY 0.25mg” is imprinted on the cap with black ink and a black radial band on the body.
Slovenian: Gilenya 0,25 mg trde kapsule imajo neprozorna pokrovček in telo kapsule slonokoščene barve.
English: Fingolimod and fingolimod phosphate concentrations increase in an apparently dose proportional manner after multiple once-daily doses of 0.5 mg or 1.25 mg.
Slovenian: Po večkratnih odmerkih 0,5 mg ali 1,25 mg enkrat dnevno se koncentraciji fingolimoda in fingolimodijevega fosfata zvišujeta na videz sorazmerno z višino odmerka.
English: The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are expected to prescribe/use ARCALYST are provided with a physician information pack containing the following:
Slovenian: Imetnik dovoljenja za promet z zdravilom (MAH) mora zagotoviti, da bodo pred prihodom zdravila na trg vsi zdravniki, ki nameravajo predpisovati/uporabljati zdravilo Arcalyst, prejeli paket izobraževalnega gradiva za zdravnike, ki bo vseboval naslednje:
English: • The risk of serious infections, including opportunistic bacterial, viral and fungal infections in patients treated with ARCALYST;
Slovenian: • o tveganju resnih okužb, vključno z oportunističnimi bakterijskimi, virusnimi in glivičnimi okužbami, pri bolnikih, zdravljenih z zdravilom Arcalyst;
English: • The need to measure neutrophil counts prior to initiating treatment, after 1 to 2 months and periodically thereafter while receiving ARCALYST as treatment with ARCALYST should not be initiated in patients with neutropenia;
Slovenian: • o potrebi, da določijo koncentracijo nevtrofilcev pred uvedbo zdravljenja, po 1 do 2 mesecih in nato v rednih presledkih, vse dokler bolnik prejema zdravilo Arcalyst, ker se zdravljenje z zdravilom Arcalyst pri bolnikih z nevtropenijo ne sme uvesti;
English: • The unknown safety of ARCALYST in pregnant and lactating women, thus the need for physicians to discuss this risk with patients if they become or plan to become pregnant;
Slovenian: • o dejstvu, da ni znano, ali je zdravilo Arcalyst za nosečnice in doječe ženske varno ali ne, zaradi česar je potrebno, da se zdravniki pogovorijo o tem tveganju z bolnicami, če zanosijo ali načrtujejo nosečnost;
English: • Patient Alert Card
Slovenian: • opozorilno kartico za bolnika.
English: Date of first authorisation: 03 May 2013
Slovenian: Datum prve odobritve: 3. maj 2013
English: When to take and for how long
Slovenian: Kdaj zdravilo uporabiti in kako dolgo
English: Date of first authorisation: 11 December 2007 Date of latest renewal: 24 September 2012
Slovenian: Datum prve odobritve: 11. december 2007 Datum zadnjega podaljšanja: 24. september 2012
English: They may increase the risk of bleeding.
Slovenian: Povečajo lahko tveganje za krvavitve.
English: Adults, including the elderly
Slovenian: Odrasli, vključno s starostniki
English: Its use is not recommended in these patients until further data become available.
Slovenian: Njegova uporaba pri teh bolnikih ni priporočljiva, dokler ne bodo na voljo nadaljnji podatki.
English: Use a single dose as soon as you remember.
Slovenian: Vkapajte si en odmerek takoj, ko se spomnite.
English: Do not give this medicine to children and adolescents below 18 years old because the safety and efficacy in this population has not been established.
Slovenian: Tega zdravila ne smete dati otrokom in mladostnikom, mlajšim od 18 let, ker varnost in učinkovitost pri tej populaciji nista bili dokazani.
English: Prostaglandin analogues
Slovenian: Prostaglandinski analogi
English: Contact your doctor immediately if your eyes become more red or more painful whilst using the drops.
Slovenian: Nemudoma se posvetujte s svojim zdravnikom, če vaše oči postanejo bolj rdeče ali bolj boleče med uporabo kapljic.
English: Considering their mechanism of action, the concomitant use of these medicinal products is not recommended.
Slovenian: Glede na njihov mehanizem delovanja pa sočasna uporaba teh zdravil ni priporočljiva.
English: Additionally, nearly all patients received prophylactic treatment with antibiotics, according to clinical practice at each of the clinical trial sites.
Slovenian: Poleg tega so skoraj vsi bolniki prejeli profilaktično zdravljenje z antibiotiki, v skladu s klinično prakso vsakega od centrov za izvedbo kliničnega preskušanja.
English: Nepafenac has not been evaluated in long-term carcinogenicity studies.
Slovenian: Nepafenaka niso ovrednotili z dolgoročnimi študijami kancerogenosti.
English: Also tell your doctor if you are taking medicines that reduce blood clotting (warfarin) or other NSAIDs.
Slovenian: Svojemu zdravniku povejte tudi, če jemljete zdravila, ki zmanjšujejo strjevanje krvi (varfarin) ali druge NSAID.
English: However, efficacy beyond day 14 post operation was not measured.
Slovenian: Vendar učinkovitosti po 14. dnevu po operaciji niso ocenjevali.
English: Rare: cutis laxa (dermatochalasis), allergic dermatitis
Slovenian: Redki: cutis laxa (dermatohalazija), alergijski dermatitis
English: One drop in the affected eye or eyes, three times a day - morning, midday, and evening.
Slovenian: Ena kapljica v prizadeto oko ali očesi, trikrat na dan - zjutraj, opoldan in zvečer.
English: How to use Wash your hands before you start.
Slovenian: Kako uporabljati zdravilo Najprej si umijte roke.
English: The recommended dose is One drop in the affected eye or eyes, once a day.
Slovenian: Priporočeni odmerek je ena kapljica v prizadeto oko ali očesi, enkrat na dan.
English: For storage conditions after first opening of the medicinal product, see section 6.3
Slovenian: Za pogoje shranjevanja po prvem odprtju zdravila glejte poglavje 6.3.
English: You can usually carry on using the drops, unless you experience serious side effects.
Slovenian: Običajno lahko nadaljujete z uporabo kapljic, razen če so neželeni učinki resni.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
English: Interactions mediated by protein binding are also unlikely.
Slovenian: Tudi interakcije zaradi vezave zdravila na beljakovine so malo verjetne.
English: Side effects with frequency not known (cannot be estimated from the available data)
Slovenian: Neželeni učinki z neznano pogostnostjo (je ni mogoče oceniti iz razpoložljivih podatkov)
English: Do not drive or use machines until your vision is clear.
Slovenian: Ne vozite avtomobila in ne upravljajte orodij ali strojev, dokler se vam ne zbistri vid.
English: Throw away the bottle 4 weeks after first opening, to prevent infections.
Slovenian: Kapalni vsebnik zavrzite 4 tedne po tem, ko ste ga prvič odprli, tako boste preprečili okužbe.
English: In vitro studies have demonstrated a very low potential for interaction with other medicinal products and protein binding interactions (see section 5.2).
Slovenian: Študije in vitro so pokazale zelo majhno možnost za medsebojno delovanje z drugimi zdravili in interakcije vezave na beljakovine (glejte poglavje 5.2).
English: See leaflet for further information.
Slovenian: Preberite priloženo navodilo za nadaljnje informacije.
English: The following adverse reactions are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from available data).
Slovenian: Naslednji neželeni učinki so razvrščeni po naslednjem dogovoru: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000) ali neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
English: If it is almost time for the next dose, leave out the missed dose and continue with the next dose of your regular routine.
Slovenian: Če je že skoraj čas za naslednji odmerek, preskočite izpuščeni odmerek in nadaljujte z naslednjim rednim odmerkom.
English: There are no adequate data regarding the use of nepafenac in pregnant women.
Slovenian: Ni ustreznih podatkov o uporabi nepafenaka pri nosečnicah.
English: Geriatric population
Slovenian: Geriatrična populacija
English: Radiochromatographic analyses before and after β-glucuronidase hydrolysis indicated that all metabolites were in the form of glucuronide conjugates, with the exception of amfenac.
Slovenian: Radiokromatografske analize pred in po hidrolizi z β-glukuronidazo so pokazale, da so se vsi presnovki pojavili v obliki glukuronidnih konjugatov, z izjemo amfenaka.
English: Inflammation clearing and pain free rates were similar for both products at all postoperative evaluations.
Slovenian: Stopnje zmanjšanja vnetja in odsotnosti bolečine so bile podobne za obe zdravili pri vseh pooperativnih vrednotenjih.
English: • Gently squeeze the sides of the bottle until one drop is released into your eye (picture 2).
Slovenian: • Rahlo stisnite stranici kapalnega vsebnika, dokler ne iztisnete kapljice v oko (slika 2).